Peyton Jacob, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
jacob_peyton

Research Chemist, Department of Psychiatry, UCSF

peyton@itsa.ucsf.edu

Phone: (415) 282-9495 (voice)
Box 0482, UCSF
San Francisco, CA 94143-0482


Education

University of California, Davis, B.A., 1969, Chemistry
Purdue University, Lafayette, IN, Ph.D., 1975, Organic Chemistry
University of California, San Francisco, Postdoc, 1975-78, Pharmaceutical Chemistry

Professional Experience

  • 1969-1975
    Teaching and Research Assistant, Department of Chemistry, Purdue University, W. Lafayette, Indiana
  • 1975-1978
    NIH Postdoctoral Fellow, Department of Pharmaceutical Chemistry, University of California, San Francisco, California
  • 1978-6/84
    Assistant Research Chemist, Departments of Medicine and Psychiatry, University of California, San Francisco, and Division of Clinical Pharma-cology, San Francisco General Hospital Medical Center
  • 7/84-7/90
    Associate Research Chemist, Departments of Medicine and Psychiatry, University of California, San Francisco, and Division of Clinical Pharmacology, San Francisco General Hospital
  • 7/90-present
    Research Chemist, Depts. of Medicine and Psychiatry, University of California, San Francisco, and Div. of Clinical Pharmacology, San Francisco General Hospital Medical Center

Honors & Awards

  • 1975-78
    NIH Postdoctoral Fellow
  • 1973-74
    Allied Chemical Corporation Fellow

Selected Publications

  • (From a Total of 152)
  • Haller CA, P Jacob III, and NL Benowitz. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther, 75:259-273, 2004.
  • Jacob P, III, CA Haller, M Duan, L Yu, M Peng, and NL Benowitz. Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids. J Anal Toxicol, 28:152-159, 2004.
  • Haas JS, CP Kaplan, D Barenboim, P Jacob, III, and NL Benowitz. Bupropion in breast milk: An exposure assessment for potential treatment to prevent post-partum tobacco use. Tobacco Control, 13:52-56, 2004.
  • Benowitz NL, OF Pomerleau, CS Pomerleau, and P Jacob, III. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res, 5:621-624, 2003.
  • Dietrich M, G Block, NL Benowitz, JD Morrow, M Hudes, P Jacob, III, EP Norkus, and L Packer. Vitamin C supplementation decreases oxidative stress biomarker F2-isoprostane in plasma of nonsmokers exposed to environmental tobacco smoke. Nutrition and Cancer, 45:176-184, 2003.
  • Benowitz NL, Peng M, Jacob P III. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharmacol Ther, 74:468-474, 2003.
  • Benowitz NL, A Hannson, P Jacob III: Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39:1107-1112, 2002.
  • Benowitz NL, EJ Perez-Stable, B Herrera, and P. Jacob, III: Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 94:108-115, 2002.
  • Campbell BJ, Rowbotham M, Davies PS, Jacob P, III, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 91(5): 1343-50, 2002.
  • Dempsey D, P Jacob III, NL Benowitz: Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 301:594-598, 2002.
  • Haller CA, P Jacob III, NL Benowitz: Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clin Pharmacol Ther 71:421-432, 2002.
  • Jacob P, III, D Hatsukami, H Severson, S Hall, L Yu, NL Benowitz: Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev, 11:1668-1673, 2002.
  • Jacob P, III, M Wilson, L Yu, J Mendelson, RT Jones: Determina-tion of 4-hydroxy-3-methoxyphenyl-ethylene glycol-4 sulfate in human urine using liquid chromatography-tandem mass spectrometry. Anal Chem 74:5290-5296, 2002.
  • Benowitz NL, P Jacob, III: Trans-3'-hydroxycotinine: Disposition kinetics, effects, and plasma levels during cigarette smoking. Br J Clin Pharmacol 51:53-59, 2001.
  • Zevin S, S Saunders, SG Gourlay, P Jacob, III, NL Benowitz: Cardiovascular effects of carbon monoxide and cigarette smoking. J Am Coll Cardiol, 38:1633-1638, 2001.
  • Benowitz NL, P Jacob III: Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism Clin Pharmacol Ther 67:653-659, 2000.
  • Dempsey D , P Jacob III, NL Benowitz Nicotine metabolism and elimination kinetics in the newborn. Clin Pharmacol Ther 67:458-465, 2000.
  • Jacob P III, W Yu, L Yu, NL Benowitz: Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. J Pharm Biomed Anal 23:653-661, 2000.
  • Zevin S, P Jacob III, P Geppetti, NL Benowitz: Nicotine-mecamylamine interactions. Clin Pharmacol Ther 68:58-66, 2000.
  • Zevin S, P Jacob III, P Geppetti, NL Benowitz: Clinical pharmacology of oral cotinine. Drug Alcohol Depend 60:13-18, 2000.
  • Jacob P III, AT Shulgin, NL Benowitz: Minor tobacco alkaloids as biomarkers for tobacco use: Comparison of cigarettes, smokeless tobacco, cigar and pipe users. Am J Public Health 89:731-736, 1999.
  • Panganiban K, P Jacob III, ET Everhart, EC Tisdale, SL Batki, JE Mendelson, RT Jones: Sulfon-ium salts as deri-vatizing agents. 3. Quantitation of the cocaine metabolite benzoylecgonine in urine using gas chromatography with ion-pair extraction/on-column alkylation. J Anal Toxicol 23:581-585, 1999.
  • Gelal A, P Jacob III, L Yu, NL Benowitz: Disposition kinetics and effects of menthol. Clin Pharmacol Ther 66:128-135, 1999.
  • Dempsey, DA, P Jacob III, JC Partridge, RT Jones, MC Rowbotham: The elimination half-life of cocaine and benzoylecgonine in neonates. J Anal Toxicol 23:24-28, 1999.
  • Jacob P III, GD Byrd: Use of gas chromatographic and mass spectrometric techniques for the determination of nicotine and its metabolites In: Analytical Determination of Nicotine and Related Compounds and Their Metabolites, edited by J W Gorrod and P Jacob, III. Elsevier, Amsterdam, pp 191-224.
  • Benowitz NL, S Zevin, P Jacob, III: Suppression of nicotine intake during ad libitum cigarette smoking by high dose transdermal nicotine. J Pharmacol Exp Ther 287:958-962, 1998.
  • Zevin, S, P Jacob III, N Benowitz: Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 64:87-95, 1998.
  • Perez-Stable EJ, B Herrera, P Jacob III, NL Benowitz: Nicotine metabolism and intake in black and white smokers. J Am Med Assn 280:152-156, 1998.
  • Denaro CP, P Jacob III, NL Benowitz: Evaluation of pharmacokinetic methods used to estimate caffeine clear-ance and comparison with a bayesian forecasting method. Ther Drug Monit 20:78-87, 1998.
  • Henderson, GL, MR Harkey, C Zhou, RT Jones, P Jacob III: Incorporation of isotopically labeled cocaine into human hair: Race as a factor. J Anal Toxicol 22:156-165, 1998.
  • Benowitz NL, P Jacob III, J Slade, L Yu: Nicotine content of the Eclipse nicotine delivery device (Ltr). Am J Public Health 87:1865-1866, 1997.
  • Jacob, P, M Ulgen, JW Gorrod: Metabolism of (S)-(-)-nicotine by guinea pig and rat brain: Identi-fication of cotinine. Eur J Drug Metabol Pharmacokin 22:391-394, 1997.
  • Everhart ET, P Cheung, P Shwonek, K Zabel, EC Tisdale, P Jacob, III, J Mendelson, RT Jones: Subnanogram level measurement of buprenorphine in human plasma by electron-capture, capil-lary gas chromatography: Application to pharmacokinetics of sub-lingual bupre-norphine. Clin Chem 43:2292-2302, 1997.
  • Zevin S, P Jacob III, N Benowitz: Cotinine effects on nicotine metabolism. Clin Pharma-col Ther 61:649-654, 1997.
  • Eldirdiri, N, M Ulgen, P Jacob, JW Gorrod: The in vitro metabolism of norcotinine and related bio-trans-formation products by microsomal preparations. Eur J Drug Metabol Pharma-co-kin 22:385-390, 1997.